LivaNova PLC reported a decrease in worldwide sales by 3.2 percent and a GAAP diluted loss per share of $2.96 for Q4 2019. The adjusted diluted earnings per share were $1.00. The company faced challenges due to a component supplier issue for oxygenators and execution problems in the Rest of World region.
Worldwide sales decreased by 3.2 percent on a reported basis.
GAAP diluted loss per share from continuing operations was $2.96.
Adjusted diluted earnings per share from continuing operations were $1.00.
Strong sales in Advanced Circulatory Support (ACS) and stability in the Epilepsy business were noted.
LivaNova anticipates sales growth between 3 and 5 percent on a constant-currency basis and adjusted diluted earnings per share in the range of $3.10 to $3.30 for full-year 2020. Adjusted cash flow from operations, excluding litigation payments, is projected to be $180 to $200 million, with capital expenditures ranging from $25 to $35 million.
Visualization of income flow from segment revenue to net income